A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete
source: shutterstock.com

A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete

  AIV001 (axitinib): a potential, non-surgical therapeutic option for people with basal cell carcinoma (BCC). AiViva Biopharma describes AIV001 as: a novel formulation of a multi-kinase inhibitor combined with AiViva’s…

Continue Reading A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete
Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH
source: shutterstock.com

Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH

According to a story from Healio, Rohit Kohli, MBBS, MS, division chief of gastroenterology, hepatology and nutrition at Children’s Hospital Los Angeles, spoke at the World Congress on Insulin Resistance, Diabetes…

Continue Reading Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH
Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference
source: shutterstock.com

Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference

Nathan Ehrlich, age 40, has had more health troubles than the average person, to say the least. As a teenager, he was diagnosed with leukemia. Thanks to the support of…

Continue Reading Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference